TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 0.700nMAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 2nMAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A(Homo sapiens (Human))
Pfizer
Curated by ChEMBL
Pfizer
Curated by ChEMBL
Affinity DataIC50: 3.90nMAssay Description:Inhibition of human Phosphodiesterase 7A1 expressed in baculovirus infected Sf9 cellsMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 4nMAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 4nMAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 4nMAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 5nMAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 5nMAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 5nMAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
Affinity DataIC50: <5nMAssay Description:The kinase activity was measured by DELFIA/time-resolved fluorometry. The reaction was carried out in 96-well polypropylene plates and was terminated...More data for this Ligand-Target Pair
Affinity DataIC50: <5nMAssay Description:The kinase activity was measured by DELFIA/time-resolved fluorometry. The reaction was carried out in 96-well polypropylene plates and was terminated...More data for this Ligand-Target Pair
Affinity DataIC50: <5nMAssay Description:The kinase activity was measured by DELFIA/time-resolved fluorometry. The reaction was carried out in 96-well polypropylene plates and was terminated...More data for this Ligand-Target Pair
Affinity DataIC50: <5nMAssay Description:The kinase activity was measured by DELFIA/time-resolved fluorometry. The reaction was carried out in 96-well polypropylene plates and was terminated...More data for this Ligand-Target Pair
Affinity DataIC50: <5nMAssay Description:The kinase activity was measured by DELFIA/time-resolved fluorometry. The reaction was carried out in 96-well polypropylene plates and was terminated...More data for this Ligand-Target Pair
Affinity DataIC50: <5nMAssay Description:The kinase activity was measured by DELFIA/time-resolved fluorometry. The reaction was carried out in 96-well polypropylene plates and was terminated...More data for this Ligand-Target Pair
Affinity DataIC50: <5nMAssay Description:The kinase activity was measured by DELFIA/time-resolved fluorometry. The reaction was carried out in 96-well polypropylene plates and was terminated...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 5.68nMpH: 7.5 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 6nMAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 6nMAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 7.40nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 7.5nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 8nMAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 8.35nMpH: 7.5 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 9nMAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 9.03nMpH: 7.5 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 10nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 11nMAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 11nMAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 12nMAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 12nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 12 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 13nMpH: 7.4 T: 2°CAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 13nMAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 13nMpH: 7.4 T: 2°CAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 13nMpH: 7.4 T: 2°CAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 14nMAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
Affinity DataIC50: 15nMAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 12 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 15nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 15nMpH: 7.4 T: 2°CAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 16nMpH: 7.4 T: 2°CAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 16nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 16nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 16.3nMpH: 7.5 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 16.8nMpH: 7.5 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 18nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 18nMpH: 7.4 T: 2°CAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 19nMpH: 7.4 T: 2°CAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 19nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1 [L188C](Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 19nMAssay Description:The enzyme was assayed with substrate GST- retinoblastoma in the presence of 25 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which in...More data for this Ligand-Target Pair
TargetHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A(Homo sapiens (Human))
Pfizer
Curated by ChEMBL
Pfizer
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibition of human Phosphodiesterase 7A1 expressed in baculovirus infected Sf9 cellsMore data for this Ligand-Target Pair